Assessment of the efficacy of lanreotide autogel in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly

Trial Profile

Assessment of the efficacy of lanreotide autogel in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2005

At a glance

  • Drugs Lanreotide; Octreotide
  • Indications Hypertension; Left ventricular hypertrophy; Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top